Drug

Sirolimus Albumin-bound Nanoparticles clinical trials

Also written ABI-009.

studies test it: 20
open now: 3
in phase 3: 0
first study started: 2007

Keep track of what changes. Save the Sirolimus Albumin-bound Nanoparticles studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

20 studies that test it; most in 2018 (4)

Studies that test Sirolimus Albumin-bound Nanoparticles, by start year
Year	Studies
2007	1
2015	1
2016	1
2017	3
2018	4
2019	1
2022	3
2023	3
2024	2
2026	1

By phase

A phase 1/2 study counts in both.

Early Phase 1: 1
Phase 1: 10
Phase 2: 11

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms: 3
Neuroendocrine Tumors: 2
Leiomyosarcoma: 1
Ovarian Neoplasms: 1
Neoplasm Metastasis: 1
Carcinoma: 1
Central Nervous System Neoplasms: 1
Pulmonary Arterial Hypertension: 1
Colorectal Neoplasms: 1
Glioblastoma: 1
Drug Resistant Epilepsy: 1
Carcinoma, Renal Cell: 1

Who runs them

Industry 11 · Other 9

Aadi Bioscience, Inc. (9) · M.D. Anderson Cancer Center (1) · University of Oklahoma (1) · Sarcoma Oncology Research Center, LLC (1) · Children's Oncology Group (1) · Seattle Children's Hospital (1) · Celgene (1) · Mayo Clinic (1)

Often tested with

Tested in the same studies.

Temozolomide (2) · Gemcitabine (1) · Nivolumab (1) · Irinotecan (1) · Bevacizumab (1) · Lomustine (1) · Marizomib (1) · Adagrasib (1)

Studies

Open first, then newest update. How each study uses Sirolimus Albumin-bound Nanoparticles is read from its arms, and is right about nine times in ten.

Testing it · 20

Given in every arm · 2 — Sirolimus Albumin-bound Nanoparticles is usual care beside what is tested